249 related articles for article (PubMed ID: 21343917)
1. Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease.
Richardson RM; Kells AP; Rosenbluth KH; Salegio EA; Fiandaca MS; Larson PS; Starr PA; Martin AJ; Lonser RR; Federoff HJ; Forsayeth JR; Bankiewicz KS
Mol Ther; 2011 Jun; 19(6):1048-57. PubMed ID: 21343917
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety of MRI-guided administration of AAV2-GDNF and gadoteridol in the putamen of individuals with Parkinson's disease.
Rocco MT; Akhter AS; Ehrlich DJ; Scott GC; Lungu C; Munjal V; Aquino A; Lonser RR; Fiandaca MS; Hallett M; Heiss JD; Bankiewicz KS
Mol Ther; 2022 Dec; 30(12):3632-3638. PubMed ID: 35957524
[TBL] [Abstract][Full Text] [Related]
3. Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys.
Johnston LC; Eberling J; Pivirotto P; Hadaczek P; Federoff HJ; Forsayeth J; Bankiewicz KS
Hum Gene Ther; 2009 May; 20(5):497-510. PubMed ID: 19203243
[TBL] [Abstract][Full Text] [Related]
4. Glial-derived neurotrophic factor gene transfer for Parkinson's disease: anterograde distribution of AAV2 vectors in the primate brain.
Kells AP; Forsayeth J; Bankiewicz KS
Neurobiol Dis; 2012 Nov; 48(2):228-35. PubMed ID: 22019719
[TBL] [Abstract][Full Text] [Related]
5. Anterograde axonal transport of AAV2-GDNF in rat basal ganglia.
Ciesielska A; Mittermeyer G; Hadaczek P; Kells AP; Forsayeth J; Bankiewicz KS
Mol Ther; 2011 May; 19(5):922-7. PubMed ID: 21102559
[TBL] [Abstract][Full Text] [Related]
6. Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys.
Su X; Kells AP; Huang EJ; Lee HS; Hadaczek P; Beyer J; Bringas J; Pivirotto P; Penticuff J; Eberling J; Federoff HJ; Forsayeth J; Bankiewicz KS
Hum Gene Ther; 2009 Dec; 20(12):1627-40. PubMed ID: 19671001
[TBL] [Abstract][Full Text] [Related]
7. Image-guided convection-enhanced delivery of GDNF protein into monkey putamen.
Gimenez F; Krauze MT; Valles F; Hadaczek P; Bringas J; Sharma N; Forsayeth J; Bankiewicz KS
Neuroimage; 2011 Jan; 54 Suppl 1():S189-95. PubMed ID: 20080195
[TBL] [Abstract][Full Text] [Related]
8. Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain.
Hadaczek P; Kohutnicka M; Krauze MT; Bringas J; Pivirotto P; Cunningham J; Bankiewicz K
Hum Gene Ther; 2006 Mar; 17(3):291-302. PubMed ID: 16544978
[TBL] [Abstract][Full Text] [Related]
9. Real-time MR imaging with Gadoteridol predicts distribution of transgenes after convection-enhanced delivery of AAV2 vectors.
Su X; Kells AP; Salegio EA; Salegio EA; Richardson RM; Hadaczek P; Beyer J; Bringas J; Pivirotto P; Forsayeth J; Bankiewicz KS
Mol Ther; 2010 Aug; 18(8):1490-5. PubMed ID: 20551915
[TBL] [Abstract][Full Text] [Related]
10. Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys.
Eberling JL; Kells AP; Pivirotto P; Beyer J; Bringas J; Federoff HJ; Forsayeth J; Bankiewicz KS
Hum Gene Ther; 2009 May; 20(5):511-8. PubMed ID: 19254173
[TBL] [Abstract][Full Text] [Related]
11. Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease.
Bartus RT; Brown L; Wilson A; Kruegel B; Siffert J; Johnson EM; Kordower JH; Herzog CD
Neurobiol Dis; 2011 Oct; 44(1):38-52. PubMed ID: 21704161
[TBL] [Abstract][Full Text] [Related]
12. Trial of magnetic resonance-guided putaminal gene therapy for advanced Parkinson's disease.
Heiss JD; Lungu C; Hammoud DA; Herscovitch P; Ehrlich DJ; Argersinger DP; Sinharay S; Scott G; Wu T; Federoff HJ; Zaghloul KA; Hallett M; Lonser RR; Bankiewicz KS
Mov Disord; 2019 Jul; 34(7):1073-1078. PubMed ID: 31145831
[TBL] [Abstract][Full Text] [Related]
13. Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF.
Kells AP; Eberling J; Su X; Pivirotto P; Bringas J; Hadaczek P; Narrow WC; Bowers WJ; Federoff HJ; Forsayeth J; Bankiewicz KS
J Neurosci; 2010 Jul; 30(28):9567-77. PubMed ID: 20631185
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson's disease.
Whone A; Luz M; Boca M; Woolley M; Mooney L; Dharia S; Broadfoot J; Cronin D; Schroers C; Barua NU; Longpre L; Barclay CL; Boiko C; Johnson GA; Fibiger HC; Harrison R; Lewis O; Pritchard G; Howell M; Irving C; Johnson D; Kinch S; Marshall C; Lawrence AD; Blinder S; Sossi V; Stoessl AJ; Skinner P; Mohr E; Gill SS
Brain; 2019 Mar; 142(3):512-525. PubMed ID: 30808022
[TBL] [Abstract][Full Text] [Related]
15. Accuracy of direct magnetic resonance imaging-guided placement of drug infusion cannulae.
Chittiboina P; Heiss JD; Lonser RR
J Neurosurg; 2015 May; 122(5):1173-9. PubMed ID: 25594325
[TBL] [Abstract][Full Text] [Related]
16. AAV2-mediated gene delivery to monkey putamen: evaluation of an infusion device and delivery parameters.
Sanftner LM; Sommer JM; Suzuki BM; Smith PH; Vijay S; Vargas JA; Forsayeth JR; Cunningham J; Bankiewicz KS; Kao H; Bernal J; Pierce GF; Johnson KW
Exp Neurol; 2005 Aug; 194(2):476-83. PubMed ID: 16022872
[TBL] [Abstract][Full Text] [Related]
17. Depletion of AADC activity in caudate nucleus and putamen of Parkinson's disease patients; implications for ongoing AAV2-AADC gene therapy trial.
Ciesielska A; Samaranch L; San Sebastian W; Dickson DW; Goldman S; Forsayeth J; Bankiewicz KS
PLoS One; 2017; 12(2):e0169965. PubMed ID: 28166239
[TBL] [Abstract][Full Text] [Related]
18. Titer and product affect the distribution of gene expression after intraputaminal convection-enhanced delivery.
Emborg ME; Hurley SA; Joers V; Tromp do PM; Swanson CR; Ohshima-Hosoyama S; Bondarenko V; Cummisford K; Sonnemans M; Hermening S; Blits B; Alexander AL
Stereotact Funct Neurosurg; 2014; 92(3):182-94. PubMed ID: 24943657
[TBL] [Abstract][Full Text] [Related]
19. Intraputamenal infusion of GDNF in aged rhesus monkeys: distribution and dopaminergic effects.
Ai Y; Markesbery W; Zhang Z; Grondin R; Elseberry D; Gerhardt GA; Gash DM
J Comp Neurol; 2003 Jun; 461(2):250-61. PubMed ID: 12724841
[TBL] [Abstract][Full Text] [Related]
20. Optimal region of the putamen for image-guided convection-enhanced delivery of therapeutics in human and non-human primates.
Yin D; Valles FE; Fiandaca MS; Bringas J; Gimenez F; Berger MS; Forsayeth J; Bankiewicz KS
Neuroimage; 2011 Jan; 54 Suppl 1():S196-203. PubMed ID: 19761848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
